Can I Take Resveratrol with Synthroid (Levothyroxine)?

What Is Resveratrol and Why Are Women Taking It?

Resveratrol is a polyphenol found in grape skins, red wine, and Japanese knotweed. It has attracted attention for its potential effects on cellular aging, cardiovascular protection, and metabolic health. Women's use has grown sharply because of marketing that positions it as a menopause-friendly longevity supplement, with some proponents citing its weak estrogen-receptor activity as a bonus for postmenopausal women.

Supplement sales data suggest that women over 45 account for a disproportionately large share of resveratrol purchases. That age group overlaps heavily with the population most likely to be on levothyroxine: hypothyroidism affects roughly 5% of the US population, with women diagnosed at a rate approximately 7 times higher than men, and prevalence rises sharply after age 40.

What Forms and Doses Are Sold?

Over-the-counter resveratrol supplements typically provide 100-1,000 mg per capsule, far exceeding the amounts in food (a glass of red wine contains roughly 0.3-1.9 mg). Most longevity-focused protocols use 250-500 mg daily. Bioavailability of oral resveratrol is low, estimated at less than 1% of the parent compound reaching systemic circulation due to rapid glucuronidation and sulfation in the gut and liver. That metabolic quirk matters when you think about how it interacts with other drugs.

Who Is Reaching for Resveratrol?

The women most likely to combine resveratrol with Synthroid are:

• Postmenopausal women seeking anti-aging or cardiovascular benefits
• Perimenopausal women using it as a natural estrogen-adjacent supplement
• Women with PCOS who have read about resveratrol's insulin-sensitizing properties
• Women with Hashimoto thyroiditis who are supplement-curious and proactively managing thyroid autoimmunity

All four groups have good reasons to care about whether the combination is safe. The answer is nuanced enough that a single yes or no does not serve you well.

How Could Resveratrol Interact With Levothyroxine?

There is no single dramatic mechanism here. The concern comes from three overlapping pathways, each contributing a modest effect that compounds depending on your dose, your baseline TSH, and your hormonal status.

Pathway 1: CYP Enzyme Modulation

Levothyroxine is primarily metabolized by deiodination (conversion of T4 to T3 and reverse T3), glucuronidation, and sulfation. Resveratrol inhibits CYP1A2 and, to a lesser degree, CYP3A4 in vitro. CYP1A2 contributes to thyroid hormone catabolism. If resveratrol inhibits this pathway meaningfully in humans, it could slow levothyroxine clearance, theoretically raising circulating T4 levels.

The critical caveat: in vitro inhibition does not always translate to a clinically significant change in a living person taking realistic supplement doses. A 2010 pharmacokinetic study found resveratrol's CYP1A2 inhibition was relevant mainly at concentrations achievable with very high doses, not the 250-500 mg range typical of supplementation. This means the interaction is possible but not guaranteed to move your TSH in a detectable way.

Pathway 2: Estrogenic Activity and Thyroid Binding Globulin

Resveratrol binds estrogen receptors alpha and beta, acting as a selective estrogen receptor modulator (SERM). This matters for women on levothyroxine because estrogen raises thyroid binding globulin (TBG) levels. Higher TBG means more of your circulating T4 is bound and inactive, which can effectively reduce the free T4 available to your tissues.

Exogenous estrogen is a well-documented reason to require a higher levothyroxine dose: women starting oral contraceptives or estrogen-based hormone therapy often need a dose increase of 20-50 mcg. Resveratrol's estrogenic potency is far weaker than pharmaceutical estrogen, so the TBG effect is expected to be much smaller. Still, a postmenopausal woman with very little endogenous estrogen who takes high-dose resveratrol daily could see a small but real shift in free T4.

Pathway 3: Direct Thyroid Effects

In animal and cell-culture studies, resveratrol has been shown to inhibit sodium-iodide symporter (NIS) expression, the transporter that pulls iodine into thyroid follicular cells. For a woman with a functioning thyroid on no medication, this is likely irrelevant at supplement doses. For a woman on levothyroxine because her thyroid makes little or no hormone on its own, NIS suppression in residual thyroid tissue is equally irrelevant. The concern would apply to a woman on partial thyroid support whose remaining thyroid tissue is still contributing meaningfully, a situation more common with subclinical hypothyroidism than with overt hypothyroidism requiring full replacement.

The WomanRx Interaction Framework for this pair: Think of the risk as low-to-moderate and dose-dependent. At 100-250 mg/day resveratrol, the probability of a clinically detectable TSH change is low. At 500-1,000 mg/day, particularly in a postmenopausal woman or anyone already titrating her levothyroxine dose, a 6-8 week TSH recheck is not optional, it is sensible standard practice.

Absorption Timing: Does Separation Help?

Levothyroxine absorption is notoriously sensitive. The FDA labeling for levothyroxine states that it should be taken on an empty stomach 30-60 minutes before food, and that a long list of substances including calcium, iron, and certain polyphenols can reduce absorption by 20-40%.

Resveratrol is a polyphenol. Polyphenols can chelate and bind to various compounds in the gut. While no published study has directly measured resveratrol's effect on levothyroxine absorption in a controlled human trial, the chemical class behavior is reason enough to apply a dose-separation strategy.

Practical guidance:

1. Take your levothyroxine first thing in the morning on an empty stomach.
2. Wait at least 4 hours before taking resveratrol.
3. If you prefer to take resveratrol in the evening, that spacing is naturally achieved.

A 4-hour window is consistent with the separation recommended for other polyphenol-containing foods and supplements interacting with levothyroxine. Your pharmacist or prescribing clinician can adjust this if your specific regimen warrants it.

Monitoring: What Numbers Actually Tell You If Something Is Off

You cannot feel a small TSH shift. Fatigue, weight gain, cold intolerance, or heart palpitations are late signs of a meaningful change. Early detection requires a lab test.

If you start resveratrol, stop it, or significantly change your dose while on levothyroxine, request a TSH measurement at 6-8 weeks. The American Thyroid Association recommends TSH retesting 6-8 weeks after any levothyroxine dose change or after introduction of a substance known to affect absorption or metabolism. Starting a new supplement qualifies.

What TSH Range Should You Be Aiming For?

Your target TSH depends on your clinical situation:

• General hypothyroidism in reproductive-age women: 0.5-2.5 mIU/L is commonly targeted, though ACOG notes the reference range of 0.5-4.5 mIU/L is acceptable outside of pregnancy.
• Trying to conceive: TSH below 2.5 mIU/L is the standard preconception target.
• Postmenopausal women: Some clinicians accept a slightly higher TSH (up to 4.0 mIU/L) given age-related reference range shifts, though this varies by guideline and individual history.

If your TSH drifts out of your personal target range after starting resveratrol, your clinician may need to adjust your levothyroxine dose rather than automatically stopping the supplement.

Life-Stage Considerations: This Is Not a One-Size Answer

Reproductive Years (Ages 18-40)

Women in this group are most likely taking resveratrol for PCOS management or general wellness. A 2022 randomized controlled trial published in Phytomedicine found that 800 mg/day resveratrol for 12 weeks improved insulin sensitivity in women with PCOS, though it had no significant effect on androgen levels compared with placebo. If you have PCOS-associated subclinical hypothyroidism (common in this group), resveratrol's modest thyroid effects warrant a baseline TSH before starting and a recheck at 6-8 weeks.

Trying to Conceive (TTC)

Stop resveratrol before actively trying to conceive. The teratogenicity data are covered in the pregnancy section below. Your TSH target tightens to below 2.5 mIU/L during this phase, and any supplement that could shift thyroid hormone levels requires extra caution.

Perimenopause (Typically Ages 45-55)

This is the highest-complexity group. Your levothyroxine dose may already be in flux as endogenous estrogen fluctuates and body composition changes. Adding a SERM-like supplement at the same time is not dangerous outright, but it adds a variable. Get a baseline TSH before starting resveratrol, then recheck at 6-8 weeks.

Postmenopause

Most women using resveratrol as a longevity supplement fall here. If you are on a stable levothyroxine dose and not taking pharmaceutical estrogen, the interaction risk is low but not zero, particularly at doses above 500 mg/day. Annual TSH monitoring (standard practice anyway) is sufficient if you are otherwise stable after the initial 6-8-week recheck.

Hashimoto Thyroiditis

Resveratrol has been studied for its anti-inflammatory properties, and some small studies have looked at whether it reduces thyroid antibody titers. A 2021 pilot study in Thyroid found no significant reduction in anti-TPO antibodies with 500 mg/day resveratrol over 12 weeks in women with Hashimoto thyroiditis, though the sample was too small to draw firm conclusions. The interaction concern remains the same as for any woman on levothyroxine.

Pregnancy, Lactation, and Contraception

Resveratrol is NOT recommended during pregnancy. This is a hard stop.

Animal studies show that resveratrol at doses comparable to human supplement use causes fetal growth restriction and adverse placental changes. Human data are absent because no ethical trial has exposed pregnant women to resveratrol supplementation. The FDA has not assigned a formal pregnancy category to dietary supplements, but the toxicology signals are sufficient for ACOG and the Society for Maternal-Fetal Medicine to advise against resveratrol use in pregnancy.

Levothyroxine, by contrast, is entirely safe and necessary in pregnancy. Untreated or undertreated hypothyroidism in pregnancy is associated with a significantly increased risk of miscarriage, preterm birth, placental abruption, and neurodevelopmental deficits in the child. Women on levothyroxine typically need a dose increase of 20-30% within the first 4-6 weeks of confirmed pregnancy. Do not stop levothyroxine. Do stop resveratrol.

Lactation

Resveratrol and its metabolites are detectable in breast milk in animal models. Human lactation data are essentially nonexistent. Given the absence of safety data, most clinicians advise stopping resveratrol during breastfeeding. Levothyroxine transfers into breast milk in very small amounts and is considered compatible with breastfeeding by LactMed/NIH.

Contraception

Resveratrol is not a teratogen in the same league as isotretinoin or methotrexate, so there is no formal contraception requirement written into its use. However, because the animal data on fetal harm are real and human data are absent, women of reproductive age who are sexually active and not trying to conceive should use effective contraception if they choose to take high-dose resveratrol (above 250 mg/day). Discuss this with your clinician.

Conditions Where This Combination Comes Up Most Often in Women

PCOS and Hypothyroidism

These two conditions co-occur in a meaningful proportion of women. Thyroid dysfunction is found in approximately 22-26% of women with PCOS depending on the diagnostic criteria used. If you have both, you may be interested in resveratrol for insulin resistance while already taking levothyroxine. The 4-hour separation rule and a 6-8-week TSH recheck apply.

Postpartum Thyroiditis

Some women develop transient thyroiditis after delivery and are prescribed a short course of levothyroxine. Adding resveratrol during this window (while also managing a newborn and potentially breastfeeding) is not advisable. Wait until your thyroid status is fully resolved and you are no longer nursing.

Osteoporosis and Bone Health

Postmenopausal women sometimes combine resveratrol with other bone-protective strategies. A 2017 randomized trial in the Journal of Clinical Endocrinology and Metabolism found that 75 mg/day resveratrol for 16 weeks modestly improved lumbar spine bone mineral density in postmenopausal women compared with placebo. That dose is lower than the typical longevity supplement dose and may carry less interaction risk.

Female Pattern Hair Loss

Hypothyroid-related hair loss is a common reason women check their TSH. Adding resveratrol will not treat thyroid-related alopecia, and if resveratrol shifts your TSH, it could make it worse. Address the thyroid optimization first.

Who This Combination Is Reasonable For vs. Who Should Be More Careful

Reasonable, with monitoring:

• Postmenopausal women on stable levothyroxine, not using pharmaceutical estrogen, taking 100-250 mg/day resveratrol, with TSH checked at 6-8 weeks after starting
• Women with Hashimoto thyroiditis curious about resveratrol's anti-inflammatory profile, following the same monitoring approach
• Women with PCOS and subclinical hypothyroidism who have discussed the combination with their prescribing clinician

More caution warranted:

• Women actively titrating their levothyroxine dose (wait until TSH is stable before adding anything new)
• Perimenopausal women whose thyroid requirements are already shifting
• Women taking doses of 500-1,000 mg/day resveratrol, where CYP effects are more likely to be clinically detectable
• Anyone with a history of thyroid cancer on suppressive levothyroxine therapy (TSH targets are very tight; any perturbation matters)

Avoid entirely:

• Pregnant women
• Breastfeeding women
• Women trying to conceive

Evidence Gaps: What We Simply Do Not Know

Women have been under-represented in polyphenol pharmacokinetic studies, and the handful of trials specifically in women with hypothyroidism are small and short-term. The entire framework here is built on:

1. Mechanistic studies of resveratrol's CYP activity (mostly in vitro or rodent models)
2. Known class effects of polyphenols on levothyroxine absorption
3. Known effects of estrogenic compounds on TBG and free T4
4. Extrapolation from clinical experience with stronger CYP inhibitors and levothyroxine

There is no randomized controlled trial in women taking both resveratrol and levothyroxine that has measured TSH as a primary endpoint. If you are told this interaction is definitively dangerous or definitively harmless, neither speaker has read the literature carefully. The honest answer is: low-to-moderate theoretical concern, manageable with monitoring, absent in pregnancy and lactation.

Talking to Your Clinician: What to Say

Many prescribers are not familiar with resveratrol's pharmacology. You can bring these points to your appointment:

• "I want to start resveratrol at [dose]. Can we check my TSH now and again in 6-8 weeks?"
• "I will take my levothyroxine at least 4 hours before the resveratrol to minimize any absorption interaction."
• "Are there any specific reasons, given my current dose and TSH, why you would advise against trying this?"

That conversation takes three minutes and gives your clinician the information needed to support you safely.